Table 1.
Baseline characteristics by country
| Characteristic | The Netherlands | Belgium | P‐value a |
|---|---|---|---|
| N = 1186 | N = 1705 | ||
| Female sex | 502 (42.3) | 720 (42.2) | .96 |
| Age | 70.7 ± 10.0 | 71.3 ± 10.8 | .14 |
| BMI | 28.5 ± 5.3 | 28.8 ± 5.7 | .27 |
| Care setting specialty | |||
| Cardiology | 1094 (92.2) | 1484 (87.0) | <.0001 |
| Other hospital departments | 30 (2.5) | 90 (5.3) | |
| General practice | 62 (5.2) | 131 (7.7) | |
| CHF | 110 (9.3) | 263 (15.4) | <.0001 |
| Hypertension | 775 (65.5) | 1160 (68.2) | .14 |
| Diabetes Mellitus | 238 (20.1) | 279 (16.4) | .01 |
| Stroke/TIA | 134 (11.3) | 169 (9.9) | .22 |
| PE or DVT | 22 (1.9) | 41 (2.4) | .33 |
| CAD | 221 (18.6) | 289 (17.0) | .24 |
| PVD | 86 (7.3) | 135 (8.0) | .51 |
| ACS | 174 (14.7) | 164 (9.6) | <.0001 |
| CKD, moderate or severe | 118 (10.0) | 224 (13.3) | .01 |
| Previous bleeding | 25 (2.1) | 46 (2.7) | .31 |
| Risk scores | |||
| CHA2DS2‐VASc | 3.1 ± 1.5 | 3.1 ± 1.6 | .22 |
| HAS‐BLED | 1.4 ± 0.9 | 1.5 ± 0.9 | .25 |
| Antithrombotic treatment | |||
| NOAC ± AP | 209 (17.8) | 1110 (65.5) | <.0001 |
| DTI ± AP | 66/209 (31.6) | 267/1110 (24.1) | |
| FXa ± AP | 143/209 (68.4) | 843/1110 (75.9) | |
| VKA ± AP | 847 (72.1) | 247 (14.6) | |
| Acenocoumarol ± AP | 744/847 (87.8) | 54/247 (21.9) | |
| Phenprocoumon ± AP | 99/847 (11.7) | 36/247 (14.6) | |
| Warfarin ± AP | 1/847 (0.1) | 155/247 (62.8) | |
| Other or unknown ± AP | 3/847 (0.4) | 2/247 (0.8) | |
| AP monotherapy | 56 (4.8) | 179 (10.6) | |
| None | 63 (5.4) | 158 (9.3) | |
The aggregated data of all cohorts are displayed. Categorical data is presented in n (% of total) and continuous data in mean ± standard deviation, unless stated otherwise.
Abbreviations: ACS, acute coronary syndrome; AP, antiplatelet agents; BMI, body mass index (kg/m2); CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; DTI, direct thrombin Inhibitor; DVT, deep venous thrombosis; FXa, direct factor Xa inhibitor; NOAC, non–vitamin K antagonist oral anticoagulant; PE, pulmonary embolism; PVD, peripheral vascular disease; TIA, transient ischaemic attack; VKA, vitamin K antagonist.
P‐values calculated using chi‐square tests for categorical variables and t‐tests for continuous variables.